Genomic epidemiology of a dengue virus epidemic in urban Singapore.

Novartis Institute for Tropical Diseases, Chromos, Singapore.
Journal of Virology (Impact Factor: 4.65). 03/2009; 83(9):4163-73. DOI: 10.1128/JVI.02445-08
Source: PubMed

ABSTRACT Dengue is one of the most important emerging diseases of humans, with no preventative vaccines or antiviral cures available at present. Although one-third of the world's population live at risk of infection, little is known about the pattern and dynamics of dengue virus (DENV) within outbreak situations. By exploiting genomic data from an intensively studied major outbreak, we are able to describe the molecular epidemiology of DENV at a uniquely fine-scaled temporal and spatial resolution. Two DENV serotypes (DENV-1 and DENV-3), and multiple component genotypes, spread concurrently and with similar epidemiological and evolutionary profiles during the initial outbreak phase of a major dengue epidemic that took place in Singapore during 2005. Although DENV-1 and DENV-3 differed in viremia and clinical outcome, there was no evidence for adaptive evolution before, during, or after the outbreak, indicating that ecological or immunological rather than virological factors were the key determinants of epidemic dynamics.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dengue virus multifunctional proteins NS3 protease/helicase and NS5 methyltransferase/ RNA-dependent-RNA-polymerase form part of the viral replication complex involved in viral RNA genome synthesis, methylation of the 5prime-cap of viral genome and polyprotein processing amongst other activities. Previous studies have shown that NS5 residue K330 is required for interaction between NS3 and NS5. Here, we show by competitive NS3-NS5 interaction ELISA that NS3 peptide spanning residues 566-585 disrupts NS3-NS5 interaction, but not the null-peptide bearing N570A mutation. Small angle X-ray scattering study on NS3172-618 helicase and covalently linked NS3172-618-NS5320-341 reveals a rigid and a compact formation of the latter, indicating that peptide NS5320-341 engages in specific and discrete interaction with NS3. Significantly, NS3 N570A mutation introduced into an infectious DENV2 cDNA clone did not yield detectable virus by plaque assay even though intracellular double-stranded RNA was detected by immunofluorescence. Detection of increased negative-strand RNA synthesis by real-time RT-PCR for NS3:N570A mutant suggests that NS3-NS5 interaction plays an important role in the balanced synthesis of positive- and negative-strand RNA for robust viral replication. DENV infection has become a global concern and the lack of safe vaccines or antiviral treatments needs to be addressed urgently. NS3 and NS5 are highly conserved amongst the four serotypes and the protein sequence around the pinpointed amino acids from the NS3 and NS5 regions are also conserved. The identification of the functionally essential interaction between the two proteins by biochemical and reverse genetics methods paves the way for rational drug design efforts to inhibit viral RNA synthesis. Copyright © 2014, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 12/2014; · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In its largest outbreak, Ebola virus disease is spreading through Guinea, Liberia, Sierra Leone, and Nigeria. We sequenced 99 Ebola virus genomes from 78 patients in Sierra Leone to ~2000× coverage. We observed a rapid accumulation of interhost and intrahost genetic variation, allowing us to characterize patterns of viral transmission over the initial weeks of the epidemic. This West African variant likely diverged from central African lineages around 2004, crossed from Guinea to Sierra Leone in May 2014, and has exhibited sustained human-to-human transmission subsequently, with no evidence of additional zoonotic sources. Because many of the mutations alter protein sequences and other biologically meaningful targets, they should be monitored for impact on diagnostics, vaccines, and therapies critical to outbreak response.
    Science 09/2014; 345(6202):1369-1372. · 31.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dengue virus has four serotypes and is endemic globally in tropical countries. Neither a specific treatment nor an approved vaccine is available, and correlates of protection are not established. The standard neutralization assay cannot differentiate between serotype-specific and serotype cross-reactive antibodies in patients early after infection, leading to an overestimation of the long-term serotype-specific protection of an antibody response. It is known that the cross-reactive response in patients is temporary but few studies have assessed kinetics and potential changes in serum antibody specificity over time. To better define the specificity of polyclonal antibodies during disease and after recovery, longitudinal samples from patients with primary or secondary DENV-2 infection were collected over a period of 1 year. We found that serotype cross-reactive antibodies peaked 3 weeks after infection and subsided within 1 year. Since secondary patients rapidly produced antibodies specific for the virus envelope (E) protein, an E-specific ELISA was superior compared to a virus particle-specific ELISA to identify patients with secondary infections. Dengue infection triggered a massive activation and mobilization of both naïve and memory B cells possibly from lymphoid organs into the blood, providing an explanation for the surge of circulating plasmablasts and the increase in cross-reactive E protein-specific antibodies.
    Frontiers in Immunology 08/2014; 5:388.

Full-text (2 Sources)

Available from
May 17, 2014